Pharma, Biotechnology & Life Sciences
Pharmaceuticals, biotechnology, life sciences, hospitals and nutraceuticals.
Where integrity risk sits in pharma.
Integrity risk in pharma runs the length of the value chain, from supplier to prescriber. A single data-integrity lapse can close a plant to a regulator; a single inducement can breach UCPMP 2024 at home or the Sunshine Act in a US operation; a single counterfeit can harm a patient. BDI's leadership has run investigations inside India's largest pharmaceutical companies, and we know where to look.
India and the UAE & Dubai, in numbers.
Statistics and regulatory developments from government, regulator and industry sources. Each figure links to its source.
The pharmacy of the world, now held to tighter manufacturing, marketing and data standards at home and abroad.
Regulatory and market updates
- Revised Schedule M enforcement
MSME units that applied for extension had until 31 December 2025; the DCGI has ordered state regulators to inspect units for compliance.Source: The Week (PTI)
- UCPMP 2024
The Uniform Code for Pharmaceutical Marketing Practices 2024 bans gifts to healthcare professionals, caps samples, bars CME events abroad and requires event spend to be published, with a self-declaration by the executive head within two months of each financial year.Source: Nishith Desai Associates
- UCMPMD 2024 for medical devices
A parallel Uniform Code for Marketing Practices in Medical Devices was notified in September 2024, extending similar rules on gifts, samples, hospitality and self-declarations to device companies.Source: Outlook Business
- Biopharma SHAKTI
₹10,000 crore over five years announced in the Union Budget 2026-27 to build biopharma capability.Source: IBEF
An import-dependent market building local manufacturing, with a regional role in distribution that brings exposure to diversion and counterfeits.
Regulatory and market updates
- Health insurance growth
Health premiums rose 16.3% to Dh30 billion in 2025, raising the stakes on provider and claims fraud.Source: Khaleej Times, citing the CBUAE annual statistical report
- AML reach into trade
The 2025 AML law expands obligations relevant to trade in high-value goods and regional distribution.Source: Hadef & Partners
The integrity risks we see most often.
Exposure ratings reflect BDI's casework and the current market and regulatory environment.
Data-integrity and GMP lapses
Altered batch, laboratory or stability records and backdated GMP documents before inspections.
HCP inducements
Inducements routed through CMEs, camps, sponsorships or consulting fees in breach of UCPMP 2024.
Counterfeit and spurious drugs
Fakes and look-alikes at chemists and on marketplaces.
Procurement and capex fraud
Kickbacks and bid rigging on APIs, KSMs, packaging and capital projects.
IP and know-how leakage
Leakage of formulations and tech-transfer data in CDMO relationships.
Channel and distributor leakage
Trade-scheme, discount and claim leakage at distributors, and stock diverted across territories, channels or price bands.
Global, hospital and US exposure
Agents in higher-risk export markets, rebate and tender manipulation in hospital channels, and HCP payments in US operations that must be reported under the Sunshine Act.
Other challenges
Regulatory convergence
Schedule M, USFDA 21 CFR Part 11 and EU expectations converge on data integrity.
Field-force scale
Thousands of medical representatives and events are hard to monitor.
Pricing pressure
Price controls and generics competition squeeze margins.
Talent mobility
Scientists and sales leaders move with know-how and relationships.
The rulebook this sector is tested against
India
- UCPMP 2024
- UCMPMD 2024 (medical devices)
- Prevention of Corruption Act, 1988
- Drugs and Cosmetics Act, Schedule M
- Companies Act s.177
- SEBI LODR
- DPDP Act, 2023
- Income-tax rules on HCP-related spend
- Trade Marks Act and Legal Metrology
United States and global
- Physician Payments Sunshine Act (CMS Open Payments)
- US Anti-Kickback Statute
- USFDA 21 CFR Part 11
- US FCPA
- UK Bribery Act
Each risk, matched to a response.
The practice that leads and the platform that keeps the record.
| Risk | How BDI responds | Practice | Platform |
|---|---|---|---|
| Data-integrity and GMP lapses | Data-integrity investigations on lab systems, audit trails and email; pre-inspection integrity checks. | ||
| HCP inducements | UCPMP compliance and HCP spend assurance: camps, CMEs, samples and fees tested, live CME monitoring, field-force expense analytics and training for field, marketing and medical teams. | ||
| Counterfeit drugs | Market surveys, test purchases, source investigations and marketplace takedowns. | ||
| Procurement and capex fraud | Procure-to-pay and capex forensic review with vendor–employee mapping. | ||
| IP and know-how leakage | Insider investigations with device forensics and partner background checks. | ||
| Channel and distributor leakage | Distributor and trade-scheme audits against secondary sales, diversion checks, market surveys and test purchases. | ||
| Global, hospital and US exposure | FCPA and UK Bribery Act risk assessment of agents, due diligence on export partners and acquisition targets, post-acquisition integrity reviews, and Sunshine Act and Open Payments assurance for US operations. |
UCPMP Compliance and HCP Spend Assurance
We test every rupee spent on healthcare professionals against the Uniform Code for Pharmaceutical Marketing Practices 2024, and build the evidence behind the executive head's annual self-declaration.
What the Code requires
What we do
- 01
Review of camp expenses
Health, screening and diagnostic camps tested for need, attendance, vendor bills and cost per beneficiary.
- 02
Live monitoring of CME events
Unannounced physical and virtual attendance: speakers, delegates, agenda, venue and hospitality checked against approvals.
- 03
Policy framework assessment
Gap review and redesign of UCPMP, anti-bribery, gifts and whistle-blower policies and the code of conduct.
- 04
Independent UCPMP reviews
Periodic, proactive testing of HCP spend against UCPMP 2024 and the anti-bribery framework.
- 05
HCP fees and fair market value
Speaker, advisory and research fees tested for genuine need, market rates and work actually delivered.
- 06
Samples and brand reminders
Samples reconciled to prescriber, pack count and the 2% cap; brand reminders checked against the ₹1,000-per-item limit.
- 07
Third-party risk assessment
Event agencies, distributors, liaison agents and consultants screened and risk-rated against the Code.
- 08
Field-force expense audit
Medical representatives' claims tested against tour plans, CRM call logs and geo-tagged visits.
- 09
Expense allowability and tax checks
Withholding compliance on benefits, allowability of HCP-related spend under income-tax law, and GST input tax credit eligibility.
- 10
Continuous monitoring
Red-flag analytics across expense, CRM and event data that surface deviations as they happen.
- 11
Training and awareness
In-person, virtual and web-based sessions for field, marketing and medical teams, through the Brand Defence Academy.
- 12
Complaint and notice support
Help responding to complaints before an association's Ethics Committee for Pharma Marketing Practices, with a risk-based review and a maintained evidence file.
How a review runs
- 01ScopeBrands, divisions, period and spend heads agreed.
- 02CollectExpense, CRM, sample and event data pulled.
- 03TestAnalytics and sample testing flag outliers.
- 04VerifyField visits and live CME checks confirm the facts.
- 05ReportFindings, fixes and self-declaration support.
This is a summary of the service. For a deeper understanding of how it would work for your organisation, please reach out to us.
Talk to a BDI partnerSunshine Act and Open Payments assurance for US operations
Indian pharmaceutical and medical-device companies that sell covered products in the United States, directly or through a US subsidiary, can be applicable manufacturers under the Physician Payments Sunshine Act. They must report payments and other transfers of value to US prescribers and teaching hospitals to the Centers for Medicare & Medicaid Services (CMS) every year, and CMS publishes the data. We help US operations get the report right, and keep HCP engagement consistent across India and the US.
What the Act requires
What we do
- 01
Applicability review
Whether the US entity, and the group behind it, is an applicable manufacturer, which products are covered and which payments are in scope.
- 02
Covered-recipient mapping
HCP master data matched to US identifiers so that every payment is attributed to the right physician, practitioner or teaching hospital.
- 03
Spend-data reconciliation
Speaker fees, consulting, meals, travel, education, research and grants reconciled from ERP, expense and event systems to the Open Payments file.
- 04
Pre-submission testing
Sample testing of the file before the 31 March deadline for completeness, nature-of-payment categories and values.
- 05
Dispute support
Handling recipient disputes in the review window and correcting records before publication.
- 06
Fair market value and Anti-Kickback review
US HCP fees tested for genuine need and market rates, alongside a review of Anti-Kickback Statute risk.
- 07
One HCP-engagement framework
Consistent rules, approvals and evidence across UCPMP in India and the Sunshine Act, Anti-Kickback Statute and state rules in the US.
- 08
Training
Sessions for US commercial, medical-affairs and finance teams on what is reportable and how to record it.
| Law | What it does |
|---|---|
| Physician Payments Sunshine Act | Section 6002 of the Affordable Care Act, 2010, implemented by CMS as the Open Payments programme (42 CFR Part 403, Subpart I). |
| US Anti-Kickback Statute | Prohibits offering or paying anything of value to induce referrals or purchases of items paid for by federal healthcare programmes. |
| State laws | Several US states, including Massachusetts, Minnesota and Vermont, add their own disclosure or gift rules for drug and device makers. |
We work alongside your US counsel. This is data, assurance and investigation work, not US legal advice.
This is a summary of the service. For a deeper understanding of how it would work for your organisation, please reach out to us.
Talk to a BDI partnerGo deeper.
Pharmaceuticals
From plant to prescriber, the integrity programme a regulator expects to see.
Explore 03.2Biotechnology
Protecting the science, the data and the people behind it.
Explore 03.3Life Sciences
Medical devices, diagnostics and CDMO services under global scrutiny.
Explore 03.4Hospitals & Healthcare
Clinical excellence depends on clean procurement, honest billing and protected patient data.
Explore 03.5Nutraceuticals & OTC
Fast-moving brands sold through every channel, and copied in every channel.
Explore
Sources
- IBEF, Pharmaceutical Industry in India, Updated Sep 2026.
- The Week, on the ASPA–CRISIL State of Counterfeiting in India 2025 report, 35% of Indians encountered fake products in one year; online platforms account for 53% of purchases, Mar 2026.
- The Week (PTI), DCGI orders inspections of pharma units to ensure compliance with revised Schedule M, Nov 2025.
- Nishith Desai Associates, Code for pharmaceutical marketing practices refurbished: no room for non-compliance, Mar 2024.
- Outlook Business, Government notifies uniform marketing code for medical devices sector, Sep 2024.
- The National, on an ADQ white paper, UAE pharma market to be valued at $4.7bn by 2025, Feb 2022.
- Khaleej Times, citing the CBUAE annual statistical report, UAE insurance premiums jump 15% to Dh74.8 billion, Aug 2026.
- Hadef & Partners, A new era for AML/CTF/PF in the UAE: Federal Decree-Law No. 10 of 2025, Oct 2025.
- Department of Pharmaceuticals, Government of India, Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Mar 2024.
- KPMG in India, Navigating the new regulatory terrain: UCPMP 2024, Mar 2024.
- Centers for Medicare & Medicaid Services, Open Payments: covered recipient review and dispute, Accessed Oct 2026.
- Baker Donelson, Medicare spreads Sunshine Act coverage to new categories of payment recipients, 2019.
- Arnold & Porter, Manufacturers may face issues and concerns under the Physician Payments Sunshine Act, Jul 2014.